BIO: Biotech cheering can't drown out industry fears

As a story in the Star-Telegram aptly notes, it's a bullish biotech industry that's meeting at BIO 2007. Ernst & Young called 2006 the "year of the deal" while industry leaders like Steven Burrill are referring to "our finest hour." But there's a dark ring around the silver cloud. Consumers are angry at the prices being charged for new drugs and investors have been far less excited about biotech companies than the big pharma companies doing deals with them. And if those big pharma wallets close, biotech could be singing a more plaintive tune at future gatherings.

- read the report from the New Jersey Star-Telegram

ALSO: E&Y crunched the numbers of public biotech companies to come up with a new ranking of biotech clusters around the U.S. San Francisco came in first, followed by New England, San Diego and New Jersey. They were followed by the Mid-Atlantic region and the Southeast, which have a far higher concentration of smaller, private developers. Report

Related Articles:
Generic legislation threatens biotech. Report
BIO outlines most prominent industry threats. Report